Cargando…

Del genoma de un patógeno a una vacuna efectiva: la vacuna de cuatro componentes frente a los meningococos del serogrupo B

Invasive meningococcal disease (IMD), caused by the bacterium Neisseria meningitidis, entails significant mortality and morbidity. Disease incidence is highest in infants <1 year and young children globally. In Europe, N. meningitidis serogroup B is responsible for over 50% of overall IMD cases,...

Descripción completa

Detalles Bibliográficos
Autores principales: Abad, Raquel, Martinón-Torres, Federico, Santolaya, Maria Elena, Banzhoff, Angelika, González-Inchausti, Carmen, Graña, Maria Gabriela, Vázquez, Julio A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedad Española de Quimioterapia 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6609940/
https://www.ncbi.nlm.nih.gov/pubmed/31148440
_version_ 1783432413645373440
author Abad, Raquel
Martinón-Torres, Federico
Santolaya, Maria Elena
Banzhoff, Angelika
González-Inchausti, Carmen
Graña, Maria Gabriela
Vázquez, Julio A.
author_facet Abad, Raquel
Martinón-Torres, Federico
Santolaya, Maria Elena
Banzhoff, Angelika
González-Inchausti, Carmen
Graña, Maria Gabriela
Vázquez, Julio A.
author_sort Abad, Raquel
collection PubMed
description Invasive meningococcal disease (IMD), caused by the bacterium Neisseria meningitidis, entails significant mortality and morbidity. Disease incidence is highest in infants <1 year and young children globally. In Europe, N. meningitidis serogroup B is responsible for over 50% of overall IMD cases, whereas the majority of IMD cases in Latin America is caused either by serogroup B or C. The development of an effective vaccine against serogroup B has challenged the researchers for over half a century. Serogroup B capsular polysaccharide was an inappropriate vaccine antigen, and the success of outer membrane vesicle (OMV) vaccines was restricted to homologous bacterial strains. Reverse vaccinology led to the development of a 4-component meningococcal vaccine including three novel antigens, and OMVs (4CMenB). Each vaccine component has a different target. 4CMenB has been authorised based on its immunogenicity and safety data because the low disease incidence precluded formal clinical efficacy studies. Human serum bactericidal antibody (hSBA) assay tests functional antibodies in the serum of vaccinated individuals (i.e. the vaccine immunogenicity), and is the accepted correlate of protection. Vaccine strain coverage has been assessed both through hSBA assays and a more conservative method named Meningococcal Antigen Typing System (MATS). Effectiveness data of 4CMenB have been collected in the field since 2013. The vaccine proved effective in outbreak control in North America, and recent data from the introduction of the vaccine in the United Kingdom infant national immunisation programme reveal a vaccine effectiveness of 82.9% for the first two doses, with an acceptable safety profile.
format Online
Article
Text
id pubmed-6609940
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Sociedad Española de Quimioterapia
record_format MEDLINE/PubMed
spelling pubmed-66099402019-07-19 Del genoma de un patógeno a una vacuna efectiva: la vacuna de cuatro componentes frente a los meningococos del serogrupo B Abad, Raquel Martinón-Torres, Federico Santolaya, Maria Elena Banzhoff, Angelika González-Inchausti, Carmen Graña, Maria Gabriela Vázquez, Julio A. Rev Esp Quimioter Revisión Invasive meningococcal disease (IMD), caused by the bacterium Neisseria meningitidis, entails significant mortality and morbidity. Disease incidence is highest in infants <1 year and young children globally. In Europe, N. meningitidis serogroup B is responsible for over 50% of overall IMD cases, whereas the majority of IMD cases in Latin America is caused either by serogroup B or C. The development of an effective vaccine against serogroup B has challenged the researchers for over half a century. Serogroup B capsular polysaccharide was an inappropriate vaccine antigen, and the success of outer membrane vesicle (OMV) vaccines was restricted to homologous bacterial strains. Reverse vaccinology led to the development of a 4-component meningococcal vaccine including three novel antigens, and OMVs (4CMenB). Each vaccine component has a different target. 4CMenB has been authorised based on its immunogenicity and safety data because the low disease incidence precluded formal clinical efficacy studies. Human serum bactericidal antibody (hSBA) assay tests functional antibodies in the serum of vaccinated individuals (i.e. the vaccine immunogenicity), and is the accepted correlate of protection. Vaccine strain coverage has been assessed both through hSBA assays and a more conservative method named Meningococcal Antigen Typing System (MATS). Effectiveness data of 4CMenB have been collected in the field since 2013. The vaccine proved effective in outbreak control in North America, and recent data from the introduction of the vaccine in the United Kingdom infant national immunisation programme reveal a vaccine effectiveness of 82.9% for the first two doses, with an acceptable safety profile. Sociedad Española de Quimioterapia 2019-06-14 2019 /pmc/articles/PMC6609940/ /pubmed/31148440 Text en © The Author 2019 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).
spellingShingle Revisión
Abad, Raquel
Martinón-Torres, Federico
Santolaya, Maria Elena
Banzhoff, Angelika
González-Inchausti, Carmen
Graña, Maria Gabriela
Vázquez, Julio A.
Del genoma de un patógeno a una vacuna efectiva: la vacuna de cuatro componentes frente a los meningococos del serogrupo B
title Del genoma de un patógeno a una vacuna efectiva: la vacuna de cuatro componentes frente a los meningococos del serogrupo B
title_full Del genoma de un patógeno a una vacuna efectiva: la vacuna de cuatro componentes frente a los meningococos del serogrupo B
title_fullStr Del genoma de un patógeno a una vacuna efectiva: la vacuna de cuatro componentes frente a los meningococos del serogrupo B
title_full_unstemmed Del genoma de un patógeno a una vacuna efectiva: la vacuna de cuatro componentes frente a los meningococos del serogrupo B
title_short Del genoma de un patógeno a una vacuna efectiva: la vacuna de cuatro componentes frente a los meningococos del serogrupo B
title_sort del genoma de un patógeno a una vacuna efectiva: la vacuna de cuatro componentes frente a los meningococos del serogrupo b
topic Revisión
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6609940/
https://www.ncbi.nlm.nih.gov/pubmed/31148440
work_keys_str_mv AT abadraquel delgenomadeunpatogenoaunavacunaefectivalavacunadecuatrocomponentesfrentealosmeningococosdelserogrupob
AT martinontorresfederico delgenomadeunpatogenoaunavacunaefectivalavacunadecuatrocomponentesfrentealosmeningococosdelserogrupob
AT santolayamariaelena delgenomadeunpatogenoaunavacunaefectivalavacunadecuatrocomponentesfrentealosmeningococosdelserogrupob
AT banzhoffangelika delgenomadeunpatogenoaunavacunaefectivalavacunadecuatrocomponentesfrentealosmeningococosdelserogrupob
AT gonzalezinchausticarmen delgenomadeunpatogenoaunavacunaefectivalavacunadecuatrocomponentesfrentealosmeningococosdelserogrupob
AT granamariagabriela delgenomadeunpatogenoaunavacunaefectivalavacunadecuatrocomponentesfrentealosmeningococosdelserogrupob
AT vazquezjulioa delgenomadeunpatogenoaunavacunaefectivalavacunadecuatrocomponentesfrentealosmeningococosdelserogrupob